Global pulmonary drugs market is expected to grow with a CAGR of 4.3% over the forecast period from 2019-2025

Tuesday, January 28, 2020 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Jan. 27, 2020 /PRNewswire/ --

The report on the global pulmonary drugs market provides qualitative and quantitative analysis for the period from 2017 to 2025.

Read the full report: https://www.reportlinker.com/p05473377/?utm_source=PRN

The report predicts the global pulmonary drugs market to grow with a CAGR of 4.3% over the forecast period from 2019-2025. The study on pulmonary drugs market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific, and RoW for the period of 2017 to 2025.The report on pulmonary drugs market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global pulmonary drugs market over the period of 2017 to 2025. Moreover, the report is a collective presentation of primary and secondary research findings.Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global pulmonary drugs market over the period of 2017 to 2025. Further, IGR- Growth Matrix gave in the report brings an insight into the investment areas that existing or new market players can consider.Report Findings1) Drivers• Growing prevalence chronic obstructive pulmonary disease (COPD)• Potential advantages of the pulmonary route as an alternative to oral and parenteral delivery methods• Rising incidence of lung diseases2) Restraints• Less awareness regarding pulmonary drugs delivery3) Opportunities• Increasing government initiativesResearch MethodologyA) Primary ResearchOur primary research involves extensive interviews and analysis of the opinions provided by the primary respondents. The primary research starts with identifying and approaching the primary respondents, the primary respondents are approached include1. Key Opinion Leaders associated with Infinium Global Research2. Internal and External subject matter experts3. Professionals and participants from the industryOur primary research respondents typically include1. Executives working with leading companies in the market under review2. Product/brand/marketing managers3. CXO level executives4. Regional/zonal/ country managers5. Vice President level executives.B) Secondary ResearchSecondary research involves extensive exploring through the secondary sources of information available in both the public domain and paid sources. At Infinium Global Research, each research study is based on over 500 hours of secondary research accompanied by primary research. The information obtained through the secondary sources is validated through the crosscheck on various data sources.The secondary sources of the data typically include1. Company reports and publications2. Government/institutional publications3. Trade and associations journals4. Databases such as WTO, OECD, World Bank, and among others.5. Websites and publications by research agenciesSegment CoveredThe global pulmonary drugs market is segmented on the basis of drug class, application, and distribution channel.The Global Pulmonary Drugs Market by Drug Class• Long-acting Beta2-agonists (LABA)• Short-acting Beta2-agonists (SABA)• Anticholinergics• Inhaled Corticosteroids (ICS)• Antihistamines• Vasodilators• Other drug classThe Global Pulmonary Drugs Market by Application• Pulmonary Arterial Hypertension• Cystic Fibrosis• Asthma & COPD• Other applicationsThe Global Pulmonary Drugs Market by Distribution Channel• Hospital Pharmacies• Retail Pharmacies• Drug Stores• Other Distribution ChannelsCompany Profiles• Sunovion Pharmaceuticals Inc.• AstraZeneca• Novartis AG• Bayer AG• F. Hoffmann-La Roche Ltd• GlaxoSmithKline Plc.• Teva Pharmaceutical Industries Ltd.• Merck Sharp & Dohme Corp• Boehringer Ingelheim International GmbH.• Actelion Pharmaceuticals Ltd• OthersWhat does this report deliver?1. Comprehensive analysis of the global as well as regional markets of the pulmonary drugs market.2. Complete coverage of all the segments in the pulmonary drugs market to analyze the trends, developments in the global market and forecast of market size up to 2025.3. Comprehensive analysis of the companies operating in the global pulmonary drugs market. The company profile includes analysis of product portfolio, revenue, SWOT analysis and the latest developments of the company.4. IGR- Growth Matrix presents an analysis of the product segments and geographies that market players should focus to invest, consolidate, expand and/or diversify.Read the full report: https://www.reportlinker.com/p05473377/?utm_source=PRN About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/global-pulmonary-drugs-market-is-expected-to-grow-with-a-cagr-of-4-3-over-the-forecast-period-from-2019-2025--300993402.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Premium Membership Benefits

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store